Publications
2023
2021
2019
- Jones, A. T., Yang, J., Narov, K., Henske, E. P., Sampson, J. R. and Shen, M. H. 2019. Allosteric and ATP-competitive inhibitors of mTOR effectively suppress tumor progression-associated epithelial-mesenchymal transition in the kidneys of Tsc2+/− Mice. Neoplasia 21(8), pp. 731-739. (10.1016/j.neo.2019.05.003)
- Gorman, K. M. et al. 2019. Bi-allelic loss-of-function CACNA1B mutations in progressive epilepsy-dyskinesia. American Journal of Human Genetics 104(5), pp. 948-956. (10.1016/j.ajhg.2019.03.005)
- Jones, A. T., Narov, K., Yang, J., Sampson, J. R. and Shen, M. H. 2019. Efficacy of dual inhibition of glycolysis and glutaminolysis for therapy of renal lesions in Tsc2+/− Mice1. NEOPLASIA 21(2), pp. 230-238. (10.1016/j.neo.2018.12.003)
2017
- Shen, M., Samsel, P., Shen, L. L., Narov, K., Yang, J. and Sampson, J. 2017. Assessment of response of kidney tumours to rapamycin and atorvastatin in Tsc1+/- mice. Translational Oncology 10(5), pp. 793-799. (10.1016/j.tranon.2017.07.009)
- Narov, K., Yang, J., Samsel, P., Jones, A., Sampson, J. R. and Shen, M. H. 2017. The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2+/- mice through suppression of cell proliferation and induction of apoptosis. Oncotarget, article number: 17215. (10.18632/oncotarget.17215)
- Yang, J. et al. 2017. Combination of everolimus with sorafenib for solid renal tumours in Tsc2+/- mice is superior to everolimus alone. Neoplasia 19(2), pp. 112-120. (10.1016/j.neo.2016.12.008)
2016
2015
- Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R. and Tee, A. R. 2015. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34(17), pp. 2239-2250. (10.1038/onc.2014.164)
- Yang, J. et al. 2015. Renal tumours in a Tsc2+/- mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin. Oncogene 34, pp. 922-931. (10.1038/onc.2014.17)
2013
- Yang, J., Kalogerou, M., Gallacher, J., Sampson, J. and Shen, M. 2013. Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. European Journal of Cancer 49(6), pp. 1479-1490. (10.1016/j.ejca.2012.10.027)
2012
2009
Articles
- Wu, F. et al. 2023. Power-controlled acoustofluidic manipulation of microparticles. Ultrasonics 134, article number: 107087. (10.1016/j.ultras.2023.107087)
- Wang, H. et al. 2023. Modelling hybrid acoustofluidic devices for enhancing nano- and micro-particle manipulation in microfluidics. Applied Acoustics 205, article number: 109258. (10.1016/j.apacoust.2023.109258)
- Xie, J. et al. 2021. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis. Cellular and Molecular Life Sciences 78(1), pp. 249–270. (10.1007/s00018-020-03491-1)
- Jones, A. T., Yang, J., Narov, K., Henske, E. P., Sampson, J. R. and Shen, M. H. 2019. Allosteric and ATP-competitive inhibitors of mTOR effectively suppress tumor progression-associated epithelial-mesenchymal transition in the kidneys of Tsc2+/− Mice. Neoplasia 21(8), pp. 731-739. (10.1016/j.neo.2019.05.003)
- Gorman, K. M. et al. 2019. Bi-allelic loss-of-function CACNA1B mutations in progressive epilepsy-dyskinesia. American Journal of Human Genetics 104(5), pp. 948-956. (10.1016/j.ajhg.2019.03.005)
- Jones, A. T., Narov, K., Yang, J., Sampson, J. R. and Shen, M. H. 2019. Efficacy of dual inhibition of glycolysis and glutaminolysis for therapy of renal lesions in Tsc2+/− Mice1. NEOPLASIA 21(2), pp. 230-238. (10.1016/j.neo.2018.12.003)
- Shen, M., Samsel, P., Shen, L. L., Narov, K., Yang, J. and Sampson, J. 2017. Assessment of response of kidney tumours to rapamycin and atorvastatin in Tsc1+/- mice. Translational Oncology 10(5), pp. 793-799. (10.1016/j.tranon.2017.07.009)
- Narov, K., Yang, J., Samsel, P., Jones, A., Sampson, J. R. and Shen, M. H. 2017. The dual PI3K/mTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2+/- mice through suppression of cell proliferation and induction of apoptosis. Oncotarget, article number: 17215. (10.18632/oncotarget.17215)
- Yang, J. et al. 2017. Combination of everolimus with sorafenib for solid renal tumours in Tsc2+/- mice is superior to everolimus alone. Neoplasia 19(2), pp. 112-120. (10.1016/j.neo.2016.12.008)
- Mirantes, C. et al. 2016. Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies. Blood 127(15), pp. 1907-1911. (10.1182/blood-2015-09-669036)
- Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R. and Tee, A. R. 2015. mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3. Oncogene 34(17), pp. 2239-2250. (10.1038/onc.2014.164)
- Yang, J. et al. 2015. Renal tumours in a Tsc2+/- mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin. Oncogene 34, pp. 922-931. (10.1038/onc.2014.17)
- Yang, J., Kalogerou, M., Gallacher, J., Sampson, J. and Shen, M. 2013. Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. European Journal of Cancer 49(6), pp. 1479-1490. (10.1016/j.ejca.2012.10.027)
- Kalogerou, M. et al. 2012. T2 weighted MRI for assessing renal lesions in transgenic mouse models of tuberous sclerosis. European Journal of Radiology 81(9), pp. 2069-2074. (10.1016/j.ejrad.2011.06.054)
- Yang, J., Darley, R. L., Hallett, M. B. and Evans, W. H. 2009. Low connexin channel-dependent intercellular communication in human adult hematopoietic progenitor/stem cells: Probing mechanisms of autologous stem cell therapy. Cell Communication and Adhesion 16(5-6), pp. 138-145. (10.3109/15419061003653763)
Supervision
Past projects